What are the recommended starting dose, titration schedule, contraindications, monitoring parameters, and side‑effect counseling for imipramine in an adult?

Imipramine Prescribing Guide for Adults

For adults with depression, start imipramine at 75 mg/day for outpatients or 100 mg/day for hospitalized patients, titrate gradually by 25-50 mg every 3-7 days based on response and tolerability, with maximum doses of 200 mg/day for outpatients and 250-300 mg/day for hospitalized patients. 1

Starting Dose

Outpatients: 75 mg/day, increased to 150 mg/day as tolerated. Doses over 200 mg/day are not recommended 1.

Hospitalized patients: 100 mg/day in divided doses, gradually increased to 200 mg/day. If no response after two weeks, increase to 250-300 mg/day 1.

Elderly/Adolescent patients: 30-40 mg/day initially; generally not necessary to exceed 100 mg/day 1. The guideline for Alzheimer's disease recommends 25-75 mg at bedtime for elderly patients 2.

For neuropathic pain: Start 25 mg at bedtime, increase by 25 mg every 3-7 days as tolerated, up to 150 mg/day 3. Secondary-amine TCAs (nortriptyline, desipramine) are better tolerated than tertiary amines like imipramine, particularly in elderly patients 4, 5.

Titration Schedule

• Increase by 25-50 mg increments every 3-7 days based on clinical response and tolerability 3
• Slower titration for elderly or medically frail patients to minimize anticholinergic and cardiovascular side effects 5
• For neuropathic pain, allow 6-8 weeks with at least 2 weeks at maximum tolerated dose for adequate trial 3
• Therapeutic plasma levels (imipramine + desipramine) of 175-300 ng/mL are associated with optimal response 6. Research shows mean doses of 248 mg/day (range 50-450 mg) may be needed to achieve therapeutic levels 7

Contraindications

Absolute contraindications 1:

• Concomitant use with MAO inhibitors (wait minimum 14 days after discontinuing MAOI)
• Acute recovery period after myocardial infarction
• Known hypersensitivity to imipramine or dibenzazepine compounds

Relative contraindications/Use with extreme caution:

• History of palpitations, syncope, or family history of sudden cardiac death or long QT syndrome—obtain baseline ECG before initiating 8, 9
• Cardiac conduction abnormalities
• Narrow-angle glaucoma
• Urinary retention
• Seizure disorders

Monitoring Parameters

Baseline:

• ECG to exclude long QT syndrome or conduction abnormalities, especially in patients with cardiac history or family history of sudden death 8, 9
• Blood pressure
• Mental status assessment

Ongoing monitoring:

• Clinical response and side effects at each dose adjustment
• Blood pressure (orthostatic hypotension risk)
• Cardiac monitoring if doses exceed 100 mg/day in elderly or if cardiac symptoms develop
• Therapeutic drug monitoring (TDM) if no response at 2.5 mg/kg/day or if toxicity suspected 9, 6
• Reassess need for continued treatment after 9 months; taper to lowest effective dose 2

Side Effect Counseling

Common anticholinergic effects (more pronounced with imipramine than secondary-amine TCAs) 4, 5:

• Dry mouth
• Constipation
• Urinary hesitancy
• Blurred vision
• Sedation

Cardiovascular effects:

• Orthostatic hypotension (particularly problematic in elderly)
• Tachycardia
• Cardiac conduction delays
• QRS prolongation at toxic levels

Neuropsychiatric effects:

• Mood changes, agitation, or insomnia (may appear before therapeutic benefits) 8
• Paradoxical worsening of symptoms
• Increased suicide risk in young adults (FDA black box warning)

Critical safety points:

• Potentially cardiotoxic; overdose may be fatal 8
• Store medication securely, out of reach of children and other household members
• Moderate side effects often gradually disappear with continued treatment 8
• Do not abruptly discontinue—taper gradually to reduce relapse tendency 1

When to seek immediate medical attention:

• Palpitations, chest pain, or syncope
• Severe dizziness or falls
• Urinary retention
• Confusion or severe mood changes
• Signs of overdose (severe drowsiness, seizures, cardiac arrhythmias)

Special Considerations

• Imipramine is considered third-line therapy for most indications due to safety concerns and side effect profile 8
• For enuresis in children ≥6 years: 25 mg at bedtime, may increase to 50 mg (<12 years) or 75 mg (≥12 years). Do not exceed 2.5 mg/kg/day 1
• Single daily dosing at bedtime is as effective as divided doses and improves adherence 10
• Maintenance therapy: 50-150 mg/day after remission, continued for 4-12 months minimum 5, 1